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AIMS: Modulation of DNA base excision repair (BER) has the potential to enhance response to chemotherapy and improve outcomes
in tumours such as melanoma and glioma. APE1, a critical protein in BER that processes potentially cytotoxic abasic sites (AP sites), is
a promising new target in cancer. In the current study, we aimed to develop small molecule inhibitors of APE1 for cancer therapy.
METHODS: An industry-standard high throughput virtual screening strategy was adopted. The Sybyl8.0 (Tripos, St Louis, MO, USA)
molecular modelling software suite was used to build inhibitor templates. Similarity searching strategies were then applied using
ROCS 2.3 (Open Eye Scientific, Santa Fe, NM, USA) to extract pharmacophorically related subsets of compounds from a chemically
diverse database of 2.6 million compounds. The compounds in these subsets were subjected to docking against the active site of the
APE1 model, using the genetic algorithm-based programme GOLD2.7 (CCDC, Cambridge, UK). Predicted ligand poses were ranked
on the basis of several scoring functions. The top virtual hits with promising pharmaceutical properties underwent detailed in vitro
analyses using fluorescence-based APE1 cleavage assays and counter screened using endonuclease IV cleavage assays, fluorescence
quenching assays and radiolabelled oligonucleotide assays. Biochemical APE1 inhibitors were then subjected to detailed cytotoxicity
analyses.
RESULTS: Several specific APE1 inhibitors were isolated by this approach. The IC50 for APE1 inhibition ranged between 30 nM and
50 mM. We demonstrated that APE1 inhibitors lead to accumulation of AP sites in genomic DNA and potentiated the cytotoxicity of
alkylating agents in melanoma and glioma cell lines.
CONCLUSIONS: Our study provides evidence that APE1 is an emerging drug target and could have therapeutic application in patients
with melanoma and glioma.
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Monofunctional alkylating agents are routinely used for the
treatment of patients with advanced melanoma and glioma.
However, the response rate to chemotherapy is modest and the
overall prognosis is poor. The cytotoxicity of alkylating agents is
directly related to their propensity to induce genomic DNA
damage. However, the ability of cancer cells to recognize this
damage and initiate DNA repair is an important mechanism for
therapeutic resistance that negatively impacts upon therapeutic
efficacy. Pharmacological inhibition of DNA repair, therefore, has
the potential to enhance the cytotoxicity of alkylating agents and
improve patient outcomes (Madhusudan and Hickson, 2005;
Madhusudan and Middleton, 2005).
The DNA base excision repair (BER) pathway is critically
involved in the repair of bases that have been damaged by alkyl-
ating agents such as temozolomide and dacarbazine (Hoeijmakers,
2001). Although there is more than one sub-pathway of BER, in
most cases base excision is initiated by a DNA glycosylase, which
recognizes a damaged base and cleaves the N-glycosidic bond,
leaving a potentially cytotoxic apurinic/apyrimidinic (AP) site
intermediate (Hickson et al, 2000). This product is a target for the
human AP endonuclease (APE1). The DNA repair domain of APE1
cleaves the phosphodiester backbone on the 50 side of the AP site
resulting in a single-strand break, which is further processed by
proteins of the BER pathway. AP endonuclease 1 accounts for over
95% of the total AP endonuclease activity in human cell lines
(Demple et al, 1991). In addition to its DNA repair activity, APE1
also performs functions such as redox regulation (mediated
through a separate redox domain) and transcriptional regulation
(Xanthoudakis et al, 1992; Okazaki et al, 1994; Bhakat et al, 2003).
AP endonuclease 1 is a member of the highly conserved
exonuclease III family of AP endonucleases, named after the
E. coli homologue of APE1 (Barzilay and Hickson, 1995). The
endonuclease IV family of AP endonucleases, the prototypical
member of which is E. coli endonuclease IV (Ramotar, 1997), is
structurally unrelated to APE1, despite being able to carry out the
comparable AP site incision reaction (Mol et al, 1995; Gorman
et al, 1997; Hosfield et al, 1999).
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Using either antisense oligonucleotides or RNA interference
approaches, several groups have reported that depletion of
intracellular APE1 sensitizes mammalian cells to a variety of DNA
damaging agents (Chen and Olkowski, 1994; Walker et al, 1994;
Silber et al, 2002). In melanoma cell lines, APE1 downregulation led
to increased apoptosis, whereas APE1 overexpression conferred
protection from chemotherapy- or hydrogen peroxide-induced
apoptosis. (Yang et al, 2005). Antisense oligonucleotides directed
APE1 depletion in SNB19, a human glioma cell line lacking
O(6)-methylguanine-DNA-methyltransferase, lead to potentiation
of MMS and temozolomide cytotoxicity (Silber et al, 2002).
In patient tumours, APE1 expression may have prognostic
and/or predictive significance. We have recently shown that
APE1 expression has prognostic significance in ovarian, gastro-
oesophageal and pancreatico-biliary cancers (Al-Attar et al, 2010).
AP endonuclease 1 is also aberrantly expressed in other human
tumours and strong nuclear expression has consistently been
observed in these studies (reviewed in (Abbotts and Madhusudan,
2010)). In head and neck cancer, nuclear localisation of APE1 was
associated with resistance to chemoradiotherapy and poor out-
come (Koukourakis et al, 2001), and in cervical cancer, an inverse
relationship between intrinsic radiosensitivity and levels of APE1
has been demonstrated (Herring et al, 1998).
Preclinical and clinical studies suggest that APE1 is a viable anti-
cancer drug target. We recently initiated a drug discovery
programme to identify small molecule inhibitor-lead compounds
of APE1 (Madhusudan et al, 2005). Fluorescence-based high
throughput screening of a chemical library, as well as biochemical
and cellular investigations were undertaken. We reported the
identification and characterisation of CRT0044876 (7-nitro-1H-
indole-2-carboxylic acid), the first small molecule inhibitor of
APE1 that potentiated the cytotoxicity of alkylating agents such
as temozolomide (Madhusudan et al, 2005). The ability of
CRT0044876 to block BER has also been demonstrated indepen-
dently by other investigators (Guikema et al, 2007; Koll et al, 2008).
In a recent study, BER inhibition using CRT0044876 was shown to
confer selectively enhanced cytotoxicity in an acidic tumour
microenvironment (Seo and Kinsella, 2009). However, the ability
of CRT0044876 to block BER has not been consistently demon-
strated by other groups (Fishel and Kelley, 2007) implying that
further work needs to be done before a genuine lead inhibitor
could emerge.
Here, we report on a new structure-based drug design strategy to
identify APE1 inhibitors. This approach has allowed us to identify
several novel APE1 inhibitors that potentiate the cytotoxicity of
alkylating agents and that have potential as lead compounds for
further optimisation and development. We also present preclinical
data that support APE1 modulation as a particularly promising
new strategy in melanoma and glioma where alkylating agents
remain an important treatment modality.
MATERIALS AND METHODS
Enzymes, oligonucleotides and chemicals
Human APE1, uracil-DNA glycosylase and E. coli endonuclease IV
were obtained from New England Biolabs (Ipswich, MA, USA).
The oligonucleotides; 5- F-GCCCCCXGGGGACGTACGATATC
CCGCTCC-30 and 30-Q-CGGGGGCCCCCTGCATGCTATAGGGCG
AGG-50 (where F¼ fluorescein, Q¼ dabcyl and X¼ 3-hydroxy-2-
(hydroxymethyl)-terahydrofuran (abasic site analogue)) (Takeshita
et al, 1987) were custom-made by Eurogentec Ltd (Southampton,
UK). A uracil-containing 18-mer oligonucleotide 50-CTCGCAAG
UGGGTACCGA-30 and its complementary oligonucleotide, 50-TC
GGTACCCGCTTGCGAG-30 were synthesised by the Cancer Research
UK central services laboratory (Clare Hall, UK). The oligonucleo-
tides for the radiolabeled DNA substrates for HeLa whole-cell
extracts (WCE) assays – 18FNMR 50-GTCACCGTGXTACGACTC-30
and 18GNMR 50-GAGTCGTAGCACGGTGAC-30 – were obtained
from Trilink Biotechnologies Inc. (San Diego, CA, USA) and
Midland certified reagent company, respectively.
The monofunctional alkylating agent methyl methane sulpho-
nate (MMS) was purchased from Sigma-Aldrich (Gillingham,
Dorset, UK) and dissolved in phosphate-buffered saline.
Stock solutions of test compounds were dissolved in DMSO.
Temozolomide (TMZ) was a gift from Dr Tracey Bradshaw, School
of Pharmacy, University of Nottingham, UK. Potential APE1
inhibitors were purchased from Maybridge Chemicals (Tintagel,
UK), ChemBridge Corporation (San Diego, CA, USA), ASINEX
intelligent chemistry (Laan van Vredenoord, the Netherlands),
Life Chemicals (Braunschweig, Germany), Enamine Ltd. (Kiev,
Ukraine), Specs Chemicals (Delft, the Netherlands), ChemDiv Inc.
(San Diego, CA, USA), Ukrorgsynthesis Ltd (Kiev, Ukraine) and
Sigma-Aldrich.
Virtual screening strategy
Virtual screening was done against the high resolution crystal
structure of APE1 (PDB accession code 1BIX). Sybyl8.0 was used to
build inhibitor templates based on the previously reported APE1
inhibitor (Madhusudan et al, 2005) and three new pharmacophore
templates designed in silico (M1, M2 and M3) based on the
structural features of the APE1 active site (see results and
discussion). Using these templates, ROCS 2.3 (Open Eye Scientific,
Santa Fe, NM, USA) (Hawkins et al, 2007) was used to extract
pharmacophorically-related (Tanimoto cut-off between 0.6 and
0.75) subsets of compounds from the ZINC database (http://
zinc.docking.org/; 2008 version with ca. 2.6 million drug-like
compounds)(Irwin and Shoichet, 2005). The 1679 filtered ligands
were docked into the APE active site pocket using GOLD2.7
(Hartshorn et al, 2007). Predicted ligand poses were ranked on the
basis of two fitness scoring functions: GOLDScore (Jones et al,
1997)and ChemScore (Verdonk et al, 2003). A total of 100 docking
runs were performed for each ligand.
Fluorescence-based AP site cleavage assay
A fluorescence-based AP site cleavage assay was performed as
described previously with slight modifications (Madhusudan et al,
2005). Briefly, APE1 (50 nM) (New England Biolabs) was incubated
in a buffer system consisting of 50mM Tris-HCl, pH 8.0, 1mM
MgCl2, 50mM NaCl, 2mM DTT at 371C for 10min. 50-F-GCCCC
CXGGGGACGTACGATATCCCGCTCC-30 and its complementary
Q-labelled oligonucleotide (see above) were annealed in a buffer
containing 100 mM Tris-HCl, 50mM NaCl and 1 mM EDTA. AP-site
cleavage was initiated by addition of the annealed substrate (25 nM)
to the reaction mix. Fluorescence readings were taken at 5min
intervals during 30min incubation at 371C using an Envision
Multilabel reader from Perkins Elmer (Cambridge, UK) with a
495 nM excitation and a 512 nM emission filter. If the DNA is
cleaved at the abasic site at position 7 from the 50-end by APE1, the
6-mer fluorescein-containing product will dissociate from its
complement by thermal melting. As a result, the quenching effect
of the 30 dabcyl (which absorbs fluorescein fluorescence when in
close proximity) is lost, and APE1 activity is measured indirectly as
an increase in fluorescence signal (Figure 2A). Similar assays were
developed for monitoring the AP endonuclease activity of
endonuclease IV using a buffering system containing 10mM
HEPES-KOH, pH 7.4, 100mM KCl and 60 ng of endonuclease IV
(Trevigen, Abingdon, UK). The final DMSO concentration was
maintained at 1.2% in all assays.
APE1 wild-type and D148E polymorph was quantified using
NanoDrop 2000c spectrophotometer (Thermo Scientific, Wilmington,
NC, USA), and 50 nM of protein was used in all assays. D148E
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2000). Experiments were repeated at least five times.
Screening of virtual APE1 inhibitor candidates
APE1 was incubated with the candidate inhibitors at 100 mM (final
DMSO concentration, 1.2%) before initiating the AP site cleavage
assay described in the previous section. Those candidates that
showed490% inhibition of APE1 activity were subjected to serial
dilution experiments for IC50 calculations. In addition, screening
of potential inhibitors for their specificity (at 100 mM concen-
tration) was performed using endonuclease IV cleavage assays.
IC50 value estimations
To estimate IC50 for APE1 inhibition, the ability of the compounds to
inhibit APE1 at a range of concentrations (10 nM–100mM) were
evaluated in black 384-well plates. The reactions were set up as
before and fluorescence intensity was measured every 5min for
30min following reaction initiation. Using the initial rate values from
the assay, percent activity was calculated for each sample relative to
a negative DMSO only control. The data was fitted to a sigmoidal
dose-response model using Graphpad Prism 3.0 (GraphPad Software,
La Jolla, CA, USA) and IC50 values were determined using the
formula: % Activity¼ 100/(1þ 10(log[I]log IC 50)).
Fluorescence quenching assay
To investigate the possibility that compounds might possess
intrinsic quenching activity, fluorescence quenching assays were
performed. Briefly, the oligonucleotides 50-F-oligonucleotide (see
above) and 3-CGGGGGCCCCCTGCATGCTATAGGGCGAGG-50
were annealed as described previously. The double stranded
oligonucleotide (5 nM) was incubated with 100 mM of potential
APE1 inhibitor in a buffer consisting of 50 mM Tris-HCl, pH 8.0,
1mM MgCl2, 50mM NaCl and 2mM DTT at 371C for 30min.
Fluorescence intensity was measured every 5min. Any hits that
showed a decrease of more than 50% in the fluorescence intensity
were considered as quenchers and discarded from further analyses.
Radiolabelled oligonucleotide-based APE1 cleavage assay
This basic assay was performed as described previously
(Madhusudan et al, 2005). Briefly, a radiolabelled uracil-containing
oligonucleotide (50-CTCGCAAGUGGGTACCGA-30) was annealed
to a complementary oligonucleotide. To generate AP sites, the
annealed DNA substrate was pretreated with uracil-DNA glycosylase
and the resulting AP site was chemically reduced by the addition of
sodium borohydride. AP site cleavage reaction consisted of 50 nM
APE1 and 0.75 ng reduced AP site double-stranded oligonucleotide
incubated at 371C for 1 h. The sample was resolved on a 15%
TBE Criterion Pre Cast Gel (Bio-Rad, Hemel Hempstead, Herts,
UK) and the radiolabelled substrate and reaction products
were visualised using a phosphorImager (Molecular Dynamics,
Buckinghamshire, UK).
Whole-cell extract AP-site cleavage assay
HeLa cells – maintained in DMEM with 10% fetal bovine serum
and 1% penicillin–Streptomycin – were harvested, washed with
1 PBS, and the pellet was resuspended in cold 222mM KCl plus
protease inhibitors (0.5mM PMSF, 1 mgml1 each of Leupepetin
and Pepstatin A), incubated on ice for 30min, and clarified
by centrifugation at 12 000 g for 15min at 41C (Simeonov
et al, 2009). The supernatant WCE was retained, the protein
concentration determined using the Bio-Rad Bradford reagent, and
aliquots were stored at 801C. AP endonuclease activity assays
using 18-mer radiolabelled oligonucleotide substrates (see above)
were performed. In brief, all potential APE1 inhibitors were
incubated at 100mM concentrations with 30 ng of HeLa WCE
at room temperature for 15min in incision buffer consisting of
50mM Tris-HCl, pH 8, 1mM MgCl2, 50mM NaCl and 2mM DTT.
After incubation, 0.5 pmol 32P-radiolabeled THF-containing
18-mer double-stranded DNA substrate was added. Incision re-
actions were then carried out immediately at 371C for 5min in a
final volume of 10 ml after which the reaction was terminated by the
addition of an equal volume of stop buffer (0.05% bromophenol
blue and xylene cynol, 20mM EDTA, 95% formamide), followed by
denaturation of samples at 951C for 10min. The radiolabeled
substrate and product were separated on a standard polyacrylamide-
denaturing gel and quantified by phosphorimager analysis.
Kinetics analysis
APE1 protein (80 ng) was incubated at room temperature for
30min without or with APE1 inhibitor (5, 10 and 20 mM).
Fluorescent DNA substrate was then added to a final concentration
of 100, 200 and 500 nM (in 40ml final volume), and enzyme activity
was allowed to proceed for 30min at 371C. The percentage APE1
cleavage activity was plotted. Lineweaver–Burk plots and kinetic
parameters (kcat and KM) were determined from eight independent
data points.
Cell lines
MeWo, SKMel and MM418 melanoma cancer cell line were grown
in RPMI culture medium (supplemented with penicillin 0.06 g l1,
streptomycin 0.1 g l1 pH 7.0, 10% foetal bovine serum (FBS, PAA
Cell Culture Company, Yeovil, Somerset, UK). U89MG and SNB-19
glioma cell lines were grown in DMEM (supplemented with
penicillin 0.06 g l1, streptomycin 0.1 g l1 pH 7.0, 10% foetal
bovine serum (FBS, PAA Cell Culture Company). HUVEC
endothelial cells were grown in a special media (199 Mediaþ
HAMS F12), and supplemented with 20% heat-inactivated foetal
calf serum, 1% Hepes, 1% Glutamine, 12.5mg Human EGF, 625 ng
of Human bFGF, 3750 units of Heparin, penicillin 0.06 g l1, and
streptomycin 0.1 g l1) Only cultures with a plating efficiency of
over 70% were used for analyses.
Western blot analysis
Protein samples were prepared by lysing SKMel30, Mewo, MM418
and U89MG cells in RIPA buffer (20mM Tris, 150mM Nacl, 1%
Nonidet p-40, 0.5% sodium deoxycholate, 1mMEDTA and 0.1%
SDS) containing protease inhibitor (Sigma, Gillingham, Dorset,
UK) and phosphatase inhibitor cocktail 1 and 2 (Sigma). The
protein content of cleared lysates was quantified using the
Bradford assay. Proteins (20mg) were separated by a 10% SDS–
PAGE gel using a Tris:Glycine buffer. Following electrophoresis,
proteins were transferred onto a nitrocellulose membrane and
blocked by incubation with PBST (PBS, 0.05% Tween 20)
containing BSA/milk. Membranes were incubated with primary
antibodies (41C/overnight, APE-1, Novus Biologicals Inc., Little-
ton, CO, USA 1 : 250 dilution and Actin (Abcam, Cambridge, UK)
1 : 5000 dilution) and infrared dye-labelled secondary antibodies
(Li-cor, Cambridge, UK) (IRDye 800CW Donkey Anti-Rabbit IgG
(Hþ L)) and IRDye 680CW Donkey Anti-Mouse IgG (Hþ L) in the
dilution of 1 : 15000 for 60min. Protein expression was determined
by scanning the membranes on Licor–Odyssey’s Scanner at the
predefined intensity fluorescence channel (700 and 800 nm).
Quantification of AP sites in genomic DNA
AP sites were quantified as described previously (Madhusudan
et al, 2005). Genomic DNA was extracted from a pellet of 1 106
cells using the guanidine/detergent lysis method. Briefly, 0.5ml
APE1 inhibitors for melanoma and glioma
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of DNAzol (Helena Biosciences, Gateshead, UK) was added to the
pellet and the cell lysate was gently passed several times through a
pipette. The resultant viscous solution was centrifuged at 10 000 g
for 10min at 251C. DNA was precipitated from the supernatant
using 0.25ml of 100% ethanol by gently inverting the tube 5–8
times at room temperature for 1–3min. The DNA was washed
twice in 0.4ml of 75% ethanol. The DNA was then solubilized in
TE buffer (pH 8.0), and the final concentration was adjusted to
100mgml1 (using a Gene Quant pro spectrophotometer). AP-site
determinations were performed on the genomic DNA using an
aldehyde reactive probe assay kit using the protocol provided by
the manufacturer (BioVision Research Products, Mountainview,
CA, USA). Untreated cells were compared with cells exposed to
either MMS alone, APE1 inhibitor alone or combination of MMS
and APE1 inhibitor. DNA was extracted at 90min and AP site
quantified as described previously. All experiments were per-
formed in triplicate.
AQueous non-radioactive cell proliferation assay
(MTS assay)
To evaluate intrinsic cytotoxicity and to evaluate the potentiation
of toxicity of cytotoxic agents by APE1 inhibitors, MTS assays were
performed as per the manufacturer’s recommendation (Promega,
Southampton, UK). Briefly, 2000 cells per well (in 200 ml of
medium) were seeded into a 96-well plate. For HUVEC cells, 5 ml of
2% type 2 gelatine (Sigma) was added to the wells and the plates
were preincubated for 20min at 371C before seeding of cells. For
intrinsic cytotoxicity assessments, cells were incubated with
varying concentrations of APE1 inhibitors and the MTS assay
was performed on day 5. For potentiation experiments, cells were
preincubated with a relatively nontoxic concentration of APE1
inhibitor for 24 h and then exposed to MMS, temozolomide or
doxorubicin. Non-radioactive cell proliferation assay was con-
ducted as described previously.
RESULTS
Virtual screening
The virtual screening process requires the precise definition of the
ligand-binding site in the target protein. The DNA repair domain
active site was localised on the basis of the previously reported
10 critical amino acid residues that are essential for the AP endo-
nuclease activity of APE1 (D70, D90, E96, Y171, D210, N212, D219,
D283, D308 and H309) (Barzilay and Hickson, 1995; Barzilay et al,
1995; Rothwell and Hickson, 1996; Erzberger and Wilson, 1999;
Fritz et al, 2003; Mundle et al, 2004). The active site is a well-
defined deep V-shaped cleft, with a Mg2þ ion at its ‘elbow’
(Figure 1A).
Our virtual screening strategy was to take a known ‘first
generation’ APE1 inhibitor, plus prototypical molecular scaffolds
designed on the basis of the shape of the ligand-binding site, and
perform a rapid structure-based similarity search of a large virtual
library of drug-like molecules. ‘Hits’ from this search were then
subjected to the more computationally costly process of docking-
based evaluation. We used Sybyl8.0 to build molecular models for
the previously reported APE1 inhibitor, CRT0044876 (Figures 1B),
and to build models for three prototypical scaffolds (M1, M2
and M3) (Figures 1B) that were predicted to fit well into the
APE1 binding site cleft and interact with key residues. Template
M1 features a central tetrahedral centre bearing a potential
Mg2þ -interacting carboxylate group plus two heteroaromatic
branches that have dimensions and relative orientations designed
to fit snugly into the active site groove. Template M2 bears
the same key features, but the heteroaromatic substituents are
extended to interact with more of the groove . Template M3 bears
an additional heteroaromatic sidechain that can access a
subsidiary cleft in one branch of the ligand-binding groove
(Figures 1B).
Using these templates, a shape-based similarity searching
strategy using ROCS 2.3 (OpenEye Scientific)(Hawkins et al,
NO2
COOH
COOH
COOH
COOH NH
NH
CRT0044876
M1
M2
M3
H
N
H
N
H
N
H
N
H
N
H
N
Figure 1 Molecular Modelling. (A) The DNA repair domain active site was localised on the basis of the previously reported 10 critical amino acid residues
that are essential for the AP endonuclease activity of APE1 (D70, D90, E96, Y171, D210, N212, D219, D283, D308 and H309, see text for details). Visual
Molecular Dynamics1.8.7 was used to visualise the crystal structure of APE1. The molecular surface in the region of the V-shaped active site cleft is shown
here. (B) Sybyl8.0 was used to build inhibitor templates. Chemical structures and docked poses of the four prototypical ligands onto APE1 active site are
shown here.
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2007) was used to extract pharmacophorically related subsets of
compounds from the ZINC database (http://zinc.docking.org/;
2008 version with ca. 2.6 million drug-like compounds)(Irwin and
Shoichet, 2005). A total of 1679 virtual hits with similarities to the
templates were identified (CRT template¼ 359, M1 template¼ 373,
M2 template¼ 459 and M3 template¼ 488). The conformations of
these compounds were then energy minimised and subjected to
docking against the active site of the APE1 model. A consensus
score plot was constructed for each virtual hit by adding the
GOLDScore and ChemScore (Figure 2A). The top ranking 25% of
the compounds were shortlisted from the consensus plot and
subjected to detailed biochemical analyses.
Biochemical screening
Compounds were tested in the fluorescence APE1 cleavage assay
(Figure 2B). A total of 38 small molecule inhibitors of APE1 were
isolated. The IC50 for APE1 inhibition ranged between 30 nm to
50 mm. This report presents in silico, biochemical and cytotoxicity
analyses of seven representative compounds. 5-Fluoro-1H-indole-
2-carboxylic acid (compound 1) was originally identified using the
‘CRT0044876 (C)’ template. N-(3-benzooxazol-2-yl-4-hydroxy-
phenyl)-2-(2-naphthyloxy)acetamide (compound 2), (3-(2-naphthyl)-
5-phenyl-2,5-dihydropyrazol-1-yl]carbonylmethyl 5-nitrothiophene-2-
carboxylate (compound 3), N-(4-fluorophenyl)-2-[4-phenylsulfonyl-2-
(p-tolyl)oxazol-5-yl) sulfanyl-acetamide (compound 4) and N-(benzo
(1,3)dioxol-5-ylmethyl)-4-(2-oxo-4-(thiazol-2-ylcarbamoylmethyl-
sulfanyl)-9-thia-3,5-diazabicyclo(4.3.0) nona-4,7,10-trien-3-yl)-butan-
amide (compound 5) was identified through the M3 template. 2-(1H-
benzoimidazol-2-ylsulfanyl)-N-((3,4 dihydroxyphenyl)methyleneamino)
acetamide 1,3-bis(1,3-benzothiazol-2-ylthio)acetone (compound 6) was
identified through the M2 template and 3-benzofuran-2-yl-2-benzo-
thiazol-2-yl-3-oxo-propanenitrile (compound 7) was identified
through M1 template. The chemical structures, consensus scores
and biochemical profiles are summarised in Table 1. CRT0044876
was used as positive control (Figure 2C). Figure 2D demonstrates
a typical APE1 inhibitory profile (compound 4, IC50¼ 11 mM).
Next, we counter-screened the compounds against endo-
nuclease IV, an E.coli orthologue of APE1 that performs AP site
cleavage in a way similar to APE1 but has a structurally and
mechanistically different active site (Ramotar, 1997; Hosfield et al,
1999). We found that compounds 1-6 had no inhibitory activity
against endonuclease IV (compound 4 is shown in Figure 3A),
implying that these compounds are specific for APE1 and likely the
exonuclease III family of AP endonucleases. Whereas compound 7
also blocked endonuclease IV activity implying non-specific
activity (Figure 3B). We then tested if the compounds possessed
any intrinsic fluorescence quenching activity, which was not the
case (compound 4 is shown in Figure 3C). We next confirmed
APE1 inhibition in a radiolabelled oligonucleotide assay
(Figure 3D). To determine both selectivity and potency, the
compounds were tested in a HeLa WCE assay and categorised as
mild (o50% inhibition), moderate (50–75%) and strong inhibi-
tors (475% inhibition). Figure 4A demonstrates that Compound 4
displays strong inhibition with about 93% blockage of AP site
cleavage in the WCE assay, whereas compound 3 had no activity in
the WCE assay (Figure 4B).
Inhibitory activity of compounds against the D148E
polymorphic variant of APE1
The D148E polymorphic variant of APE1 has been implicated in
cancer predisposition including melanoma (Li et al, 2006;
Farkasova et al, 2008; Gu et al, 2009). In addition, the D148E
polymorph may also alter ionising radiation sensitivity (Hu et al,
2001). We tested if our isolated inhibitors would have differential
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Figure 2 (A) Consensus score plot was constructed by plotting Gold Score (x-axis) and Chem Score (y-axis) for the 1679 virtual APE1 inhibitor
candidates. The top ranking 25% of the compounds were shortlisted from the consensus plot and subjected to detailed biochemical analyses. (B) Primary
screening. Fluorescence-based APE1 cleavage assay is shown here. If the DNA is cleaved at the abasic site at position 7 from the 50 end by APE1, the 6-mer
fluorescein-containing product will dissociate from its complement by thermal melting. As a result, the quenching effect of the 30 dabcyl (which absorbs
fluorescein fluorescence when in close proximity) is lost, and APE1 activity is measured indirectly as an increase in fluorescence signal. For detailed protocol
see Materials and methods section. (C) APE1 inhibition by CRT0044876 is shown here. Control¼ no APE1 in reaction. (D) APE1 inhibition by compound 4
is shown here (IC50¼ 11mM).
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Table 1 Biochemical profiling of APE1 inhibitors
APE1 inhibitors Structure Template Score
APE1
(IC50)
Endo IV
inhibition Quencher
WCE
Inhibitiona xLogP
Mol.
Wt
Compound 1 (5-fluoro-1H-indole-2-carboxylic acid) CRT 67.46 10 mM None no mild 1.14 178.14
Compound 2 (N-(3-benzooxazol-2-yl-4-hydroxy-phenyl)-
2-(2-naphthyloxy)acetamide)
M3 98.12 25 mM None no Moderate 5.4 410.43
Compound 3 ((3-(2-naphthyl)-5-phenyl-2,5-dihydropyrazol-1-yl)
carbonylmethyl 5-nitrothiophene-2-carboxylate)
M3 81.76 3 mM None no None 5.33 485.52
Compound 4 (N-(4-fluorophenyl)-2-(4-phenylsulfonyl-2-
(p-tolyl)oxazol-5-yl) sulfanyl-acetamide)
M3 82.39 11 mM None no strong 5.41 482.56
Compound 5 (N-(benzo(1,3) dioxol-5-ylmethyl)-4-
(2-oxo-4-(thiazol-2-ylcarbamoylmethylsulfanyl)-9-thia-3,
5-diazabicyclo(4.3.0) nona-4,7,10-trien-3-yl)-butanamid
M3 83.56 12 mM None no Moderate 2.52 543.652
Compound 6 (1,3-bis(1,3-benzothiazol-2-ylthio)acetone) M2 81.84 3 mM None no Strong 5.04 388.564
Compound 7 (3-benzofuran-2-yl-2-benzothiazol-2-yl-3-
oxo-propanenitrile)
M1 93.28 2 mM yes no Moderate 3.57 318.357
Abbreviation: Mol. wt¼molecular weight. aWhole-cell extracts AP site cleavage inhibition: mild;o50% inhibition, Moderate; 50–75% inhibition, strong;475%, xLogP¼ octanol/
water partition coefficient (o5 is useful for drug likeness).
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Figure 3 Secondary biochemical screening. (A) Fluorescence-based endonuclease IV cleavage assay is shown here. Compound 4 was tested at 100 mM
and showed no inhibition of endonuclease IV. Control¼ no endonuclease IV in reaction (B). Compound 7 was tested at 100 mM and showed complete
inhibition of endonuclease IV. Control¼ no endonuclease IV in reaction (C) Fluorescence queching assay did not reveal any quenching effect by
compound 4. Control¼ no inhibitor in reaction (D). Radiolabelled assay showing inhibition of AP-site cleavage by APE1. Absence of 8-mer lower band
indicates APE1 inhibition. See Material and methods for protcol details.
APE1 inhibitors for melanoma and glioma
MZ Mohammed et al
658
British Journal of Cancer (2011) 104(4), 653 – 663 & 2011 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
activity against the variant compared with the wild-type protein.
Although the AP-site cleavage activity of D148E variant was similar
to that of the wild type (Figure 4C), consistent with a previous
report (Hadi et al, 2000), Figure 4D demonstrates that for
compound 4, the IC50 for APE1 inhibition was significantly
reduced by 50.5% for the D148E protein (5.56 mM) compared
with the wild type (11mM). The preferential inhibitory activity of
compound 4 towards the D148E protein was also confirmed in
radiolabelled oligonucleotide assays (data not shown). We were
not able to demonstrate preferential inhibitory activity of other
compounds either in fluorescence or radiolabelled assays.
Kinetics analyses
To evaluate potential mechanism of action of APE1 inhibitor,
kinetic analysis was performed (Figure 5). As compound 4 had the
strongest inhibitory activity (490% inhibition) in whole-cell
extracts, we selected this compound for kinetic analysis. Line-
weaver–Burk plots and kinetic parameters was determined
from eight independent data points. KM and kcat decreased at
each inhibitor concentration (compared with no inhibitor) and the
kcat/KM decreased at increasing inhibitor concentration. The data
is consistent with uncompetitive inhibition.
However, we cannot exclude the possibility that compound
4 operates as a weak uncompetitive inhibitor (meaning it binds
the protein–DNA substrate complex), as we observed a repro-
ducibly lower KM in the presence of the compound, though this is
unlikely.
Genomic AP site accumulation in cells
In order to test the biological activity of APE1 inhibitors under
physiological conditions, analysis was then undertaken in mela-
noma cell lines (MeWo, SKMel and MM418) and glioma cell lines
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Figure 4 (A) AP endonuclease activity assays using 18-mer radiolabelled oligonucleotide substrates (see Materials and methods) were performed using
HeLa whole-cell extracts (WCE). Compound 4 showed 93% inhibition of AP cleavage activity using WCE. (B) Compound 3, on the other hand did not
inhibit WCE cleavage activity. (C) Testing AP site cleavage activity in wild-type and D148 polymorph. The figure shows that the activity was similar in both
wild-type and the D148E polymorph. (D) Inhibitory activity of compound 4 against the D148E polymorphic variant of APE1 is shown here. D148E was
more sensitive to inhibition by compound 4 compared with wild type.
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Figure 5 Kinetics analysis. To evaluate potential mechanism of action of
APE1 inhibitor, kinetic analysis was performed. Lineweaver–Burk plots and
kinetic parameters determined from eight independent data points (note:
error bars are in some cases too small to see) for compound 4 is shown
here. The APE1 inhibitor was tested at three dose levels (5, 10 and 20 mM)
and oligonucleotide substrate was evaluated at three different concentra-
tions (100, 200 and 500 nM). The reaction was performed as described in
methods. KM and kcat decreased at each inhibitor concentration (compared
with no inhibitor) and the kcat/KM decreased at increasing inhibitor
concentration. The data is consistent with uncompetitive inhibition.
APE1 inhibitors for melanoma and glioma
MZ Mohammed et al
659
British Journal of Cancer (2011) 104(4), 653 – 663& 2011 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
(U89MG and SNB-19). We initially tested if these cell lines
expressed APE1 protein. Robust APE1 expression was seen in these
cell lines using western blot analyses (Figures 6A and 7A). In order
to confirm that the isolated inhibitors block APE1 function in
living cells, the aldehyde reactive probe assay that allows
quantification of genomic AP sites was utilised in this study.
Figure 6B shows that compared with untreated cells, glioma cells
exposed to compound 4 accumulated AP sites confirming target
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Figure 6 (A) APE1 expression in glioma cell lines is shown here. (B) (1 and 2). Aldehyde reactive probe assay. U89MG cells were pretreated with 10 mM
of compound 4 alone or MMS (600 mM) or a combination of compound 4 and MMS. Genomic DNA extracted at 90min for AP-site quatification. The
combination treatment led to increased AP site content in the genomic DNA. (C) Inhibitor alone at 10mM was relatively nontoxic to cells (as shown in
Figure 7D). We took the survival fraction as 100%. The percentage survival for those cells exposed to both inhibitor and temozolomide was plotted as
a relative survival to cells exposed to the inhibitor alone. Potentiation of cytotoxicity of MMS by compound 4 (10 mM) in U89MG cell line is shown here.
(D) Potentiation of temozolomide by compound 4 (10 mM) in U89MG cell line is shown here.
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Figure 7 (A) APE1 expression in melanoma cell lines is shown here. (B) Inhibitor alone at 10mM was relatively nontoxic to cells (as shown in Figure 7D).
We took the survival fraction as 100%. The percentage survival for those cells exposed to both inhibitor and temozolomide was plotted as a relative survival
to cells exposed to the inhibitor alone. Potentiation of cytotoxicity of MMS by compound 4 (10 mM) in SK-Mel30 cell line is shown here. (C) Potentiation of
temozolomide by compound 4(10 mM) in SK-Mel30 cell line is shown here. (D) Toxicity of compound 4 in HUVEC, SK-Mel30 and U89MG is shown here.
Compound 4 was relatively nontoxic to HUVEC cells.
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inhibition in vivo. As AP sites are obligatory intermediates during
the repair of MMS-induced base damage, accumulation of AP sites
were also demonstrated in cells exposed to MMS alone. Moreover,
AP-site accumulation in cells exposed to a combination of APE1
inhibitor and MMS was more than the cells exposed to either agent
alone. Similar accumulation of AP sites was also demonstrated in
melanoma cells.
Cytotoxicity analysis in melanoma, glioma and HUVEC
endothelial cell lines
APE1 inhibitors were then tested for their inherent toxicity in
melanoma and glioma cell lines. Whereas compound 1 was non-
toxic (GI504300 mM), the GI50 (cell growth inhibition) ranged
between 1 and 50 mM for the other APE1 inhibitors: compound
2¼ 50 mM, compound 3¼ 1 mM, compound 4¼ 17 mM (glioma cell
lines) and 20 mM (melanoma cell lines), compound 5¼ 14 mM,
compound 6¼ 50mM and compound 7¼ 40 mM. We investigated if
at relatively non-toxic concentrations, APE1 inhibitors would
potentiate the cytotoxicity of monofunctional alkylating agents
MMS. Figures 6C and D demonstrate that compound 4 signi-
ficantly potentiated the cytotoxicity of MMS and temozolomide
in U89MG glioma cell line. Similar potentiation was also
demonstrated in SNB-19 glioma cell line. Figures 7B and C
demonstrates the potentiation of cytotoxicity in SK-Mel30
melanoma cell line. Similar potentiation was also demonstrated
in MeWo and MM418 melanoma cell lines. Potentiation of
cytotoxicity was also demonstrated with other APE1 inhibitors
that showed moderate to strong WCE AP-site cleavage inhibition
(compound 2, 5 and 6) but not with mild WCE AP-site cleavage
inhibition (compound 1). Compound 7, which was a non-specific
inhibitor (i.e blocked both APE1 and endonuclease IV), did
not show any potentiation of cytotoxicity and Compound 3, which
was a specific APE1 inhibitor but had no activity in WCE assay,
also did not shown any potentiation of cytotoxicity (data not
shown).
To exclude non-specific activity and potentiation, we performed
toxic studies using doxorubicin. Compound 4 did not potentiate
the cytotoxicity of doxorubicin in melanoma (SK-Mel30) and
glioma cell line (U89MG) (Figures 8A and B). Similar results were
seen for MeWo, MM418 and SNB-19 cells.
In order to investigate whether APE1 inhibitor was toxic to non-
cancer cells, we conducted toxicity analysis in HUVEC endothelial cells.
Figure 7D shows that compound 4 was relatively non-toxic to HUVECs
compared with melanoma (SK-Mel30) and glioma (U89MG) cell lines.
Similar results were seen for MeWo, MM418 and SNB-19 cells.
DISCUSSION
The overall prognosis of advanced melanoma and glioma remains
poor and strategies to improve tumour response to chemotherapy
remain a high priority. Blocking DNA repair may enhance cell kill
in cancer and improve outcomes (Madhusudan and Hickson, 2005;
Madhusudan and Middleton, 2005). APE1, a critical protein in
BER, is involved in the pathogenesis of glioma and melanoma.
Elevated AP endonuclease activity is frequently seen in human
glioma tumours(Bobola et al, 2001). Moreover, in preclinical
studies, antisense oligonucleotides directed APE1 depletion in
SNB19, a human glioma cell line lacking O(6)-methylguanine-
DNA-methyltransferase, lead to potentiation of MMS and temo-
zolomide cytotoxicity, implying that pharmacological modulation
of APE1 is a promising strategy in glioma (Silber et al, 2002).
A recent study has demonstrated that microphthalmia-associated
transcription factor (MiTF), a key transcription factor for
melanocyte lineage survival, regulates APE1 expression. Micro-
phthalmia-associated transcription factor-positive melanoma cell
lines accumulated high levels of APE1 (Liu et al, 2009). In a
separate study, downregulation of APE1 using antisense constructs
promoted apoptosis in melanoma cell lines (Yang et al, 2005).
Interestingly, the APE1 genetic polymorphism D148E may also
alter melanoma predisposition (Li et al, 2006). These studies
therefore suggest that APE1 is also a novel target in melanoma. In
this investigation, we have focussed on the development of novel
APE1 small molecule inhibitors and have provided the first
evidence that blocking APE1 is a promising strategy in melanoma
and glioma cells.
Our previous study provided the first evidence that small
molecule inhibition of APE1 is a viable anticancer strategy
(Madhusudan et al, 2005). In order to develop novel drug-like
chemotypes, we recently adopted a virtual screening approach. The
architecture of the active site of APE1 in the absence and presence of
bound AP-DNA indicates that there is little or no remodelling of the
active site upon substrate binding, a feature that is suitable for a
virtual screen (Mol et al, 1995; Gorman et al, 1997). We have
exploited the structural features of APE1 to develop an enhanced
virtual screening strategy and identified several novel small
molecule inhibitors for further drug development. Three new
pharmacophore templates were designed in silico (M1, M2 and
M3) and a total of 1679 virtual hits with similarities to the templates
were identified (CRT template¼ 359, M1 template¼ 373, M2
template¼ 459 and M3 template¼ 488). Detailed biochemical
screening showed that majority of the compounds conform to the
M3 template, which bears an additional heteroaromatic sidechain
that can access a subsidiary cleft in one branch of the ligand-binding
groove (Figures 1B). Although the structural details of M3 template
binding to APE1 active site is unknown, cocrytallization trials may
provide structural insight to guide a rational drug-design strategy.
In this study, we also provide evidence for the first time that
certain APE1 inhibitors may be more effective in blocking the
endonuclease activity of the D148E polymorph (a common
polymorph associated with cancer predisposition) compared with
the wild type. The inability of six of the seven compounds
examined to inhibit the activity of endonuclease IV provides
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presumptive evidence that the compounds indeed act by interac-
tion with APE1 rather than by obscuring the abasic site on the
DNA substrate. Moreover, the kinetics analysis has provided
insight into the mechanism of action of the inhibitor. We have
shown that compound 4 decreased KM, kcat (compared with no
inhibitor) and decreased the kcat/KM implying uncompetitive
inhibition. Future cocrytallization experiments in the presence of
DNA are likely to provide further information regarding the exact
mechanism of action of this compound. To assess potency and
specificity of our compounds, we screened their ability to block
AP-site cleavage activity using WCE. This is a good system to
screen for compounds that may have non-specific binding to other
cellular proteins. Compound 4 exhibited more than 90% inhibition
in the WCE assays, implying strong potency and specificity.
Although compound 3 blocked APE1-directed AP-site cleavage
activity in purified APE1-based assay, it had no effect in the WCE
assay. This implies that the compound has ‘off target’ non-specific
protein-binding effect and suggests that it is unlikely to be a good
development candidate.
In order to provide further preclinical evidence that blocking the
repair domain of APE1 is a potential treatment strategy, we conducted
studies in glioma and melanoma cell lines. We confirmed APE1
expression in these cancer cell lines. We then confirmed accumulation
of AP sites in vivo in cells exposed to inhibitor, providing direct
evidence of target inhibition in vivo. Intrinsic cytotoxicity for several
of the inhibitors was demonstrated in glioma and melanoma cell lines,
a finding consistent with the observation that APE1 downregulation
in melanoma cell lines promotes apoptosis, although non-specific
toxicity at higher doses of the compound cannot be excluded in our
study (Yang et al, 2005). Interestingly, the inhibitors were rela-
tively non-toxic to HUVEC cells implying selectivity to cancer cells.
In a recent study, BER inhibition using CRT0044876 was shown
to confer selectively enhanced cytotoxicity in an acidic tumour
microenvironment (Seo and Kinsella, 2009), suggesting a further
novel opportunity to target tumours. We then showed potentiation of
MMS and temozolomide cytotoxicity in melanoma and glioma cell
lines. We did not observe potentiation of doxorubicin toxicity in these
cell lines implying that APE1 inhibitor potentiates chemotherapy that
induce base damage and repaired through BER. Moreover, potentia-
tion of cytotoxicity was not demonstrated in HUVEC cells, again
implying selectivity to cancer cells. These studies indicate that APE1
inhibitors, either alone or in combination with chemotherapy, may be
a promising strategy in cancer.
Following our initial report, other investigators have identified
various APE1 inhibitors for potential pharmaceutical application
(Seiple et al, 2008; Simeonov et al, 2009; Zawahir et al, 2009). In
conclusion, these studies and our two reports (including this one),
confirm the validity of APE1 as an emerging anti-cancer drug
target.
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